Asset Details
Do you wish to reserve the book?
P75 Development of the UK severe asthma registry as a performance-monitoring quality improvement platform
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
P75 Development of the UK severe asthma registry as a performance-monitoring quality improvement platform
Do you wish to request the book?
P75 Development of the UK severe asthma registry as a performance-monitoring quality improvement platform
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
P75 Development of the UK severe asthma registry as a performance-monitoring quality improvement platform
2025
Overview
Introduction and ObjectivesThe UK Severe Asthma Registry (UKSAR) was established to facilitate research and quality improvement including performance monitoring across UK severe asthma centres. We here describe its development and refinement for the latter of those objectives. The selection of performance outcomes measures for severe asthma clinical quality improvement from clinician and patient perspectives, data collection, and assessment of clinical variation across severe asthma centres is presented.MethodsAfter relevant stakeholder consultation (patients, commissioners and clinicians), outcomes measures relating to exacerbations, oral corticosteroid exposure, asthma-related ED attendances and hospital admissions, asthma control and quality of life were selected with appropriate case-mix adjustment to help identify unexplained clinical variation. Over 2018–2025, the number of participating centres increased from 17 to 42. To date, baseline data has been entered for 18,473 patients, with data meeting the agreed quality threshold for 12,792 patients.ResultsCompared to 2018, in 2024 patients were older when first reviewed (54.0 vs 50.3 years), less likely to be never smokers (58.7% vs 65.8%) and to be on mOCS at baseline (25.5% vs 47.1%).Analysis of variation in outcomes between centres, after case-mix adjustment and allowing for effect of centre size, shows relatively few examples of significant variation in outcomes between centres. Where variation was evident, for example in improvement in asthma control ACQ6 score from baseline to follow-up (see figure 1) high-performing centres could be identified to share best-practice.Abstract P75 Figure 1Proportion of patients with positive outcomes for the above metrics, by hospital size, for patients with baseline records on or after 1 January 2022[Image Omitted. See PDF.]ConclusionsRegular discussion at UKSAR registry meetings, at which representatives from each severe asthma centre are present, of outcome measures and related latest research, including UKSAR research, together with sharing of best practice may explain why there is relatively little evidence of variation in clinical outcomes between centres. UKSAR shows that there are an increasing number year-on-year of patients on severe asthma biologic treatments and of hospitals both prescribing biologics and entering data for quality improvement. However, a limitation of UKSAR is that it cannot evaluate the presence of ‘hidden’ severe asthma not known to specialist services, a continuing issue given the harm that results from delays in appropriate diagnosis and management, and accompanying oral corticosteroid associated comorbidities.
Publisher
BMJ Publishing Group LTD
Subject
